Alejandra Gonzalez-Duarte
General Practice · New York, NYNPI 1922260348
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $127,901 of the $183,414 with a category attached, or 69.7%. 7 manufacturers reported payments, led by AstraZeneca at 55.4% of the total. Among general practice clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $705.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$102K
- Alnylam Pharmaceuticals Inc.$75K
- Pfizer$6K
- Astrazeneca UK Limited$537
- Bridgebio Pharma, Inc.$205
- AbbVie$134
- plus $45 from 1 others
Across 171 payments — averaging $1968.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$198K
- Alnylam Pharmaceuticals Inc.$73K
- Eidos Therapeutics, Inc.$66K
What the payments were for
- Consulting fees$12,9997%
- Speaking & faculty fees$127,90170%
- Travel & lodging$34,48419%
- Food & beverage$8,0304%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 134 | $101,702 |
| Alnylam Pharmaceuticals Inc. | 116 | $75,075 |
| Pfizer | 2 | $5,715 |
| Astrazeneca UK Limited | 1 | $537 |
| Bridgebio Pharma, Inc. | 5 | $205 |
| AbbVie | 1 | $134 |
| Baxter Healthcare | 1 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$183,414 in reported general payments places this provider in the 95th percentile of 5,764 general practice providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pregabalin | 31 | $1,436 |
| Mirtazapine | 20 | $122 |
Paid to pharmacies, not to this prescriber.
Other general practice in New York
- Ronnie MyersNew York$464K
- Laila AkhlaghiNew York$52K
- Vezire SarakNew York$39K
- Yohan KimNew York$38K
- Christine SkordelesNew York$32K
- Jose GorisNew York$23K
- Bruce YaffeNew York$22K
- Joseph PantaleoNew York$14K
- Jeffrey ShapiroNew York$13K
- Michael KatayevNew York$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.